Recombinant Human C-X-C chemokine receptor type 6 (CXCR6)

What is CXCR6 and what are its primary biological functions?

CXCR6 (C-X-C Motif Chemokine Receptor 6) is a G protein-coupled receptor that serves as the receptor for the chemokine CXCL16. It is predominantly expressed on immune cells, particularly T cells and NK cells. CXCR6 plays several critical biological roles:

• Acts as a receptor for the C-X-C chemokine CXCL16

• Serves as an entry coreceptor used by HIV-1 and SIV to enter target cells, in conjunction with CD4

• Controls the localization of resident memory T lymphocytes in lung compartments

• Mediates recruitment and positioning of activated CD8+ T cells in inflammatory tissues

• Maintains airway resident memory T lymphocytes, which are important for defense against respiratory pathogens

The CXCR6/CXCL16 axis is involved in various immunological processes including cell migration, adhesion, and immune surveillance, making it a focus of both basic immunology and translational research.

What cell types express CXCR6 and how can this expression be detected?

CXCR6 shows a distinctive expression pattern across different immune cell populations:

Primary CXCR6-expressing cells:

• Intratumoral CD8+ T cells (exclusive expression in many cancer types)

• Hepatic NK cells (35-55% of hepatic NK cells vs. only 3-5% of splenic NK cells)

• T cells (predominantly activated/memory subsets)

• NKT cells

Detection methods:

• Flow cytometry: Most commonly used for cellular phenotyping, using anti-CXCR6 antibodies such as PE-conjugated monoclonal antibodies

• Real-time PCR: For quantifying CXCR6 transcript levels using primers (Forward: 5′-CCCTGTACTTTATGCCTTTG-3′; Reverse: 5′-CTTGGAACTGTCCTCAGAAG-3′)

• Single-cell RNA sequencing: For detailed analysis of expression patterns across cell subpopulations

• Immunohistochemistry: For tissue localization studies

Example flow cytometry protocol:

• Isolate cells from tissue of interest (e.g., tumor, liver, PBMCs)

• Stain with fluorophore-conjugated anti-CXCR6 antibody (e.g., Mouse Anti-Human CXCR6 PE-conjugated Monoclonal Antibody)

• Co-stain with lineage markers (e.g., CD3, CD8, NK1.1)

• Analyze using standard flow cytometry techniques with appropriate controls

What experimental models are available for studying CXCR6 function?

Several experimental models have been established to study CXCR6 function:

Mouse models:

• Cxcr6^-/-^ knockout mice: Complete CXCR6 deficiency

• Cxcr6^+/-^ heterozygous mice: One allele of Cxcr6 replaced with GFP, allowing visualization of CXCR6-expressing cells

• Rag1^-/-^Cxcr6^-/-^ double knockout mice: Lack T and B cells in addition to CXCR6 deficiency, useful for studying NK cell-specific functions

• Transgenic Cxcr6^-/-^ OT-I mice: For studying antigen-specific T cell responses

In vitro systems:

• CXCR6 transfection systems in cell lines (e.g., HEK293)

• Primary human PBMC cultures with CXCR6 analysis

• Trans-well migration assays to assess CXCR6-dependent chemotaxis

• Organoid cultures with CXCR6-expressing immune cells

Disease models:

• Tumor models: Various transplantable tumor lines (e.g., Panc02-OVA, E.G7-OVA) for studying CXCR6 in cancer immunity

• Patient-derived organoids and xenografts expressing CXCL16

• Contact hypersensitivity (CHS) models for studying CXCR6 in inflammatory responses

• Viral infection models for studying CXCR6 in antiviral immunity

How can researchers effectively modify CXCR6 expression for adoptive cell therapy approaches?

Modifying CXCR6 expression has shown promising results for enhancing adoptive cell therapy efficacy, particularly for solid tumors. Here's a methodological approach:

Viral vector-based CXCR6 transduction:

• Vector design: Design retroviral or lentiviral vectors containing the CXCR6 gene, optimally with a marker gene (e.g., GFP) for tracking transduced cells

• T cell isolation: Isolate primary T cells from peripheral blood or tumor-infiltrating lymphocytes

• Activation: Activate T cells with anti-CD3/CD28 antibodies and IL-2 (typically 150 ng/mL)

• Transduction: Co-transduce cells with both CXCR6 and a tumor-specific TCR or CAR

• Verification: Confirm expression using flow cytometry and functional assays

• Expansion: Expand cells under conditions that maintain CXCR6 expression

Key considerations:

• Co-expression of CXCR6 with a tumor-specific TCR or CAR has shown synergistic effects in enhancing T cell trafficking to CXCL16-expressing tumors

• CXCR6 enhances T cell adhesion to cancer cells through interaction with CXCL16, improving tumor recognition and killing

• In experimental models, CXCR6-transduced antigen-specific T cells demonstrated significantly enhanced migration to CXCL16-expressing tumors

Experimental results from published studies:

• Co-transduction of CXCR6 with a mesothelin-specific CAR enabled effective T cell migration toward CXCL16-producing human pancreatic cancer cells

• CXCR6-transduced OT-1 T cells mediated complete tumor rejection in 4 out of 5 mice in the E.G7-OVA-CXCL16 lymphoma model

• The combination of CXCR6 with an anti-EpCAM-CAR achieved prolonged tumor control and tumor rejection in 4 out of 5 mice with Panc02-OVA-EpCAM tumors

This approach has shown particular promise for pancreatic cancer, where CXCL16 is highly expressed by both cancer cells and tumor-infiltrating immune cells .

What methodologies are optimal for investigating CXCR6's role in immune cell positioning within the tumor microenvironment?

CXCR6 plays a critical role in positioning immune cells within the tumor microenvironment. The following methodologies are valuable for studying this function:

Imaging techniques:

• Multiphoton intravital microscopy (MP-IVM): Allows real-time visualization of CXCR6+ cell movement within tumors; has been used to demonstrate that CXCR6 optimizes positioning of TCF-1neg CTL in perivascular clusters of DC3 in tumor stroma

• Confocal microscopy: For evaluating CXCR6-dependent adhesion of T cells to tumor cells

• Immunofluorescence tissue imaging: For mapping spatial distribution of CXCR6+ cells relative to other cell types

Functional assays:

• Adhesion assays: To quantify CXCR6-mediated binding to CXCL16-expressing cells

  • Protocol demonstrated that CXCR6-transduced T cells show preferential adhesion to tumor cells that can be blocked by anti-CXCL16 neutralizing antibody

• Transwell migration assays: To assess chemotactic responses to CXCL16 gradients

• In vivo tracking: Using CXCR6-GFP reporter systems to track cell movement

Molecular and cellular approaches:

• Single-cell spatial transcriptomics: To map expression patterns of CXCR6, CXCL16, and related genes within the tumor microenvironment

• CRISPR-Cas9 gene editing: For creating precise modifications to study structure-function relationships

• Adoptive transfer experiments: Comparing trafficking of wild-type versus CXCR6-deficient cells

  • Short-term (6-hour) recruitment assays have demonstrated a 33% reduction in liver localization of CXCR6-/- CD8+ T cells compared to wild-type

Key findings and considerations:

• CXCR6 promotes direct T cell adhesion to cancer cells, enhancing tumor cell recognition and killing

• CXCR6+ CD8+ T cells show improved accumulation at tumor sites, with CXCR6 deficiency resulting in reduced infiltration

• CXCL16+ macrophages and dendritic cells recruit CXCR6+ T and NK cells, which exhibit enhanced cytotoxicity

How does CXCR6 expression influence response to immune checkpoint inhibitors and what are the methodological approaches to study this relationship?

CXCR6 expression has emerged as a potential biomarker for response to immune checkpoint inhibitors. Here are methodological approaches to investigate this relationship:

Clinical correlation studies:

Experimental approaches:

• In vivo models using CXCR6-deficient mice:

  • Cxcr6-/- mice showed impaired response to anti-PD-1 treatment

  • Experimental protocol: Establish tumors in wild-type and CXCR6-deficient mice, treat with anti-PD-1 antibodies, and compare tumor growth and survival

• Mechanistic studies:

  • Analyze impact of CXCR6 deficiency on immune cell infiltration, activation, and function after checkpoint blockade

  • Study how CXCR6 affects the spatial distribution of immune cells in responders versus non-responders

Biomarker development:

• Multiparameter analysis: Combine CXCR6 expression with other known biomarkers

  • CXCR6 expression is positively correlated with established immunotherapy biomarkers:

    • CD8A expression

    • Effector T cell signature

    • PD-L1 (CD274) expression

• Immune phenotyping: Categorize tumors based on CXCR6 expression and immune infiltration patterns

  • High CXCR6 expression is significantly associated with the "inflamed" immune phenotype, which responds more favorably to immunotherapy

Data from clinical studies:

These findings suggest that CXCR6 could serve as both a prognostic biomarker and a predictive marker for immunotherapeutic response in multiple cancer types .

What approaches are most effective for studying the CXCR6-CXCL16 axis in different disease models?

The CXCR6-CXCL16 axis is involved in various disease processes. Here are effective approaches for studying this pathway across different models:

Cancer models:

• Genetic approaches:

  • Generate tumor lines with modulated CXCL16 expression (knockdown or overexpression)

  • Use CXCR6-deficient mouse models to study tumor growth and immune infiltration

• Therapeutic interventions:

  • Neutralizing antibodies against CXCL16 or CXCR6

  • Small molecule inhibitors of CXCR6 signaling

• Analysis techniques:

  • Multiplex immunohistochemistry to map CXCR6+ and CXCL16+ cells

  • Flow cytometry to characterize immune infiltrates

  • scRNA-seq to identify cell populations involved in the axis

Viral infection models:

• Hepatotropic virus models:

  • Use CXCR6-reporter systems to track memory NK cells after viral challenge

  • Employ neutralizing antibodies against CXCR6 before viral challenge

  • Results show CXCR6 is essential for NK cell-mediated antiviral immunity regardless of virus type or genetic background

• HIV/SIV models:

  • Study CXCR6 as a co-receptor for viral entry

  • Develop and test entry inhibitors targeting CXCR6

Inflammation and autoimmunity models:

• Contact hypersensitivity (CHS):

  • Use hapten sensitization and challenge in CXCR6-deficient mice

  • Adoptive transfer of CXCR6+ versus CXCR6- cells

  • CHS responses were abolished after CXCR6 blockade regardless of the type of antigen

• Graft-versus-host disease (GvHD):

  • Transfer CXCR6-deficient lymphocytes into recipients to study hepatic infiltration

  • Short-term (6-hour) recruitment assays show 33% reduction in liver localization of CXCR6-/- CD8+ T cells

Technical considerations:

• Chemotaxis assays:

  • Use Transwell systems with recombinant CXCL16 at optimal concentrations

  • Include polystyrene beads as internal standards for quantification

• CXCR6-CXCL16 interaction analysis:

  • Surface plasmon resonance for binding kinetics

  • Calcium flux assays for receptor activation

• CXCL16 detection:

  • Both membrane-bound and soluble forms must be assessed

  • ELISA for soluble CXCL16 in supernatants or plasma

  • Flow cytometry for membrane-bound CXCL16

How can single-cell RNA sequencing data be leveraged to understand CXCR6's function in different immune cell populations?

Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful tool for understanding CXCR6 biology across immune cell subsets. Here's a methodological framework:

Data generation and preprocessing:

• Sample preparation: Isolate cells from tissues of interest (tumors, inflamed tissues, blood)

• Sequencing platform selection: 10x Genomics, Smart-seq2, or other platforms depending on depth versus throughput needs

• Quality control: Filter low-quality cells and normalize expression data

• Dimensionality reduction: Apply techniques like PCA, t-SNE, or UMAP to visualize data

Analysis approaches:

• Cell type identification:

  • Identify CXCR6-expressing populations using unsupervised clustering

  • Use known cell type markers to annotate clusters

  • Studies have shown CXCR6 is predominantly expressed in T and NK cells

• Expression pattern analysis:

  • Map CXCR6 expression across cell types and activation states

  • Correlate with CXCL16 expression to identify potential interaction nodes

  • Research has demonstrated that CXCR6 facilitates T/NK-myeloid interaction via the CXCR6-CXCL16 axis

• Trajectory analysis:

  • Reconstruct developmental trajectories to determine when CXCR6 is upregulated

  • Data shows CXCR6 is upregulated on PD-1+ TCF-1neg CTL in tumor-draining lymph nodes

• Receptor-ligand interaction analysis:

  • Use computational tools (e.g., CellPhoneDB, NicheNet) to predict CXCR6-CXCL16 interactions between cell types

  • Analysis has revealed that CXCL16+ macrophages and dendritic cells recruit CXCR6+ T and NK cells

Integration with other data types:

• Spatial transcriptomics:

  • Map CXCR6+ cells within tissue architecture

  • Correlate with functional outcomes

• Multi-omics integration:

  • Combine with ATAC-seq to analyze chromatin accessibility at the CXCR6 locus

  • Integrate with proteomics data to confirm expression at protein level

Functional interpretation:

• Gene set enrichment analysis:

  • Identify pathways enriched in CXCR6+ versus CXCR6- cells

  • Research shows CXCR6+ CD8+ T cells are more immunocompetent

• Novel cell state identification:

  • Discover previously unrecognized immune cell states based on CXCR6 co-expression patterns

  • Studies have identified CXCR6 as critical for rescuing proliferative transitory CTL subsets from activation-induced cell death through exposure to trans-presented IL-15

These approaches have led to important discoveries, such as the identification of CXCR6 as the most highly expressed chemokine receptor in tumor-infiltrating CTL, and DC3 as the cell state most highly expressing its ligand CXCL16 .

What are the key experimental challenges in evaluating CXCR6's role in memory T and NK cell responses, and how can they be addressed?

CXCR6 plays a crucial role in memory formation and maintenance in both T and NK cells, but studying this function presents specific challenges:

Challenge 1: Distinguishing memory formation from maintenance

• Methodological solution: Use temporal blocking/deletion of CXCR6

  • Administer anti-CXCR6 antibody at different timepoints after primary challenge

  • Use inducible CXCR6 knockout systems

  • Research has shown that when sensitized mice were given neutralizing anti-CXCR6 before hapten challenge, CHS responses were abolished in Rag1-/- mice

Challenge 2: Tissue-specific roles of CXCR6

• Methodological solution: Tissue-specific analysis and perturbation

  • Use tissue-resident immune cell isolation protocols (avoiding contamination)

  • Perform parabiosis experiments to distinguish resident from circulating cells

  • Studies have demonstrated that 35-55% of hepatic NK cells express CXCR6, compared to only 3-5% of splenic NK cells

Challenge 3: Separating CXCR6's effects on trafficking versus function

• Methodological solution: Combined in vivo imaging and functional assays

  • Use dual-reporter systems to track both CXCR6 expression and functional markers

  • Perform short-term (6-hour) recruitment assays to isolate trafficking effects

  • Research has demonstrated a 33% reduction in liver localization of CXCR6-/- CD8+ cells compared to wild-type, while blood frequencies remained similar

Challenge 4: Heterogeneity within CXCR6+ populations

• Methodological solution: Single-cell approaches

  • Sort CXCR6+ cells based on expression level (high, intermediate, low)

  • Perform scRNA-seq on sorted populations

  • Use adoptive transfer of defined subsets to test functionality

  • Data shows CXCR6-intermediate, mostly TCF-1neg CTL emerged in the blood of tumor-bearing animals

Challenge 5: Long-term fate mapping of CXCR6+ cells

• Methodological solution: Lineage tracing approaches

  • Generate CXCR6-fate mapping mouse models

  • Use stable barcoding techniques for clonal analysis

  • Studies have shown CXCR6+ hepatic NK cells persisted unchanged for at least 6 weeks after transfer

Challenge 6: Evaluating antigen specificity of CXCR6+ memory cells

• Methodological solution: Combine CXCR6 analysis with antigen-specific tools

  • Use MHC tetramers or dextramers to identify antigen-specific cells

  • Engineer CXCR6-/- antigen-specific T cells (e.g., OT-I)

  • Research has shown induced CXCR6+CD8+ T cells possessed tumor antigen specificity and enhanced anti-PD-1 efficacy

Addressing these challenges has led to important insights, including the discovery that CXCR6 is essential for NK cell memory of haptens and viruses, being required for the persistence of memory NK cells but not their priming or effector functions .